Lakefront Biotherapeutics (LKFT) Assets (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Assets for 13 consecutive years, with $3.8 billion the latest figure, recorded in Q1 2026.

• Quarterly Assets fell 16.15% year-over-year to $3.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 billion (down 16.15% YoY) and the FY2025 annual result came in at $3.9 billion, down 17.63% from the prior year.
• Assets retreated to $3.8 billion in Q1 2026 per LKFT's latest filing, from $3.9 billion in the prior quarter.
• Over the last five years, Assets for LKFT reached as high as $5.8 billion in Q1 2022 and fell as low as $3.8 billion in Q1 2026.
• A 5-year average of $4.7 billion and a median of $4.7 billion in 2024 frame the typical range for Assets.
• Annual changes were most pronounced in 2024 — Assets declined 5.09% — and 2025, when it fell 17.63%.
• Year by year, Assets stood at $5.4 billion in 2022, then retreated by 7.96% to $5.0 billion in 2023, then fell by 5.09% to $4.7 billion in 2024, then declined by 17.63% to $3.9 billion in 2025, then retreated by 1.0% to $3.8 billion in 2026.
• According to Business Quant data, Assets over the past three periods registered $3.8 billion, $3.9 billion, and $4.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.